Figure 6
JHU-LNCaP-SM and LNCaP xenograft response to C23 administration. (A) JHU-LNCaP-SM relative xenograft size evolution over the course of treatment, the fits in transparency over the data show the equation used for doubling-time calculation. (B) Hemorrhagic appearance of JHU-LNCaP-SM tumors after 24 days of treatment with vehicle solution (IP) or C23 (2 mg/kg, IP). (C) LNCaP relative xenograft size evolution over the course of treatment, the fits in transparency over the data show the equation used for doubling-time calculation (D) PSA plasma concentrations at the start (Day 1) and the end (terminally sampled) of xenograft experiments (JHU-LNCaP-SM; 24 days; n = 6/group), LNCaP; 30 days; n = 5/group). The mean concentrations are indicated above each bar on the histogram in ng/mL (E) GDF-15 concentrations in mice plasma at the end of xenograft LNCaP assay (vehicle group n = 3; C23 group n = 3) and JHU-LNCaP-SM assay (vehicle group n = 9; C23 group n = 6) experiment evaluated by ELISA assay. (F) Spearman correlation between plasma GDF-15 (n = 8) or (G) PSA (n = 11) concentrations and xenograft tumors sizes from JHU-LNCaP-SM cell line. (H) Spearman correlation between plasma GDF-15 (n = 6) or (I) PSA (n = 9) concentrations and xenograft tumors sizes from LNCaP-SM cell line. Data are means ± SEM. *Indicates p-value < 0.05, **< 0.01, ***< 0.0001, ****< 0.0001 from a Student t-test.
